Gilotrif (Afatinib)

Giotrif (marketed in the European Union) and Gilotrif (marketed in the United States) are brand names for afatinib. It is an oral tyrosine kinase inhibitor (TKI) indicated for:

• First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations. The safety and efficacy of this medicine were not established in patients whose tumors have resistant EGFR mutations.
• Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy.

Giotrif® / Gilotrif® (afatinib) works by blocking the ErbB family of receptors (EGFR, HER2), helping slow tumor growth in EGFR mutation-positive cancers.

Recommended Dosage:
The recommended starting dose of Giotrif® / Gilotrif® in adult patients is 40 mg administered orally once daily. Take the dosage on an empty stomach (at least 1 hour before or 2 hours after a meal). Dose adjustments may be needed based on tolerance and side effects. Tablets should be swallowed whole with water.

If a dose is missed, take it within 12 hours of the scheduled time. Otherwise, skip the missed dose. Treatment continues until there is evidence of disease progression or unacceptable toxicity.

• Severe diarrhea is common with Giotrif® / Gilotrif® treatment and may lead to dehydration, kidney problems, or hospitalization if not treated promptly. Patients should begin anti-diarrheal therapy at the first sign of loose stools and maintain adequate fluid intake. Contact a healthcare provider immediately if diarrhea becomes persistent or severe.
• Serious skin reactions, including blistering, peeling, or severe rash, may occur during treatment. These conditions can become life-threatening if not recognized early. Patients should report any worsening skin symptoms immediately. Treatment may need to be interrupted or permanently discontinued depending on severity.
• Interstitial lung disease (ILD), including fatal cases, has been reported in patients receiving Giotrif® / Gilotrif®. Symptoms may include shortness of breath, cough, or fever. If ILD is suspected, treatment should be stopped immediately and evaluated. Permanent discontinuation is required if the diagnosis is confirmed.
• Liver problems, including elevated liver enzymes and rare cases of severe liver injury, may occur during treatment. Liver function tests should be monitored regularly. Patients should report symptoms such as yellowing of the skin, dark urine, fatigue, or abdominal pain promptly.
  astrointestinal perforation, although rare, has been reported and can be life-threatening. Patients with a history of ulcers, diverticulitis, or those taking certain medications may be at higher risk. Seek immediate medical attention if severe abdominal pain or unusual digestive symptoms develop.
  Eye disorders, including keratitis (inflammation of the cornea), may occur during therapy. Symptoms may include eye pain, redness, blurred vision, or sensitivity to light. Prompt ophthalmologic evaluation is required if symptoms appear. Treatment interruption may be necessary depending on severity.
• Giotrif® / Gilotrif® may cause harm to an unborn baby. Women of reproductive potential should use effective contraception during treatment and for a recommended period after the last dose. Inform your healthcare provider immediately if pregnancy occurs during therapy.
• It is not known whether afatinib passes into human breast milk. Because of the potential risk to a nursing infant, breastfeeding is not recommended during treatment and for some time after the last dose. Consult your healthcare provider for guidance.

What documents are required to import GIOTRIF® / GILOTRIF® to India?

GIOTRIF® / GILOTRIF® (afatinib) tablets can be imported by patients or government hospitals in the name of the patients only.

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

• The order will be confirmed only after the receipt of:
• A valid prescription from the Doctor
• Import permit if applicable

Is GIOTRIF® / GILOTRIF® available in India?

GIOTRIF® / GILOTRIF® (afatinib tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Giotrif® / Gilotrif® in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Giotrif® / Gilotrif® price in India.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

GIOTRIF® / GILOTRIF® can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of GIOTRIF® / GILOTRIF® (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9810469557 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Giotrif® / Gilotrif® cost in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source GIOTRIF® / GILOTRIF® (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

Are Giotrif® and Gilotrif® the same medicine?

Yes. Giotrif® and Gilotrif® contain the same active ingredient (Afatinib). The name differs based on regional branding.

What is the Generic Name for the trade name drug Giotrif® / Gilotrif®?

Afatinib is the generic name for Giotrif® (EU) and Gilotrif® (USA).

What is the Manufacturer’s Name of Giotrif® / Gilotrif®?

Giotrif® / Gilotrif® is manufactured by Boehringer Ingelheim Pharmaceuticals.

Do Giotrif® and Gilotrif® Have EMA and FDA Approval?

Both Giotrif® / Gilotrif® contain the same active ingredient, Afatinib. Giotrif® was approved in the European Union by the EMA on 25 September 2013. Gilotrif® was approved in the United States by the FDA on 12 July 2013.

What is the dosage and form of Giotrif® / Gilotrif® supplied?

Giotrif® / Gilotrif® is supplied as Tablets: 40 mg, 30 mg, and 20 mg of Afatinib for oral use.

What are the most common side effects of Giotrif® / Gilotrif® Tablets?

The most commonly reported side effects of Giotrif® / Gilotrif® are diarrhea, nausea, rash/acneiform dermatitis, stomatitis, paronychia, dry skin, decreased appetite, vomiting, and pruritus.

How does Giotrif® / Gilotrif® Import in India work?

Giotrif® / Gilotrif® Import in India is possible through the Named Patient Program. This means the medicine can be imported for a specific patient with a valid doctor’s prescription. Indian Pharma Network helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.

How much does Giotrif® / Gilotrif® Tablet cost in India?

Giotrif® / Gilotrif® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Giotrif® / Gilotrif® prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Giotrif® / Gilotrif® cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.

Can Giotrif® / Gilotrif® Tablets be available in SAARC countries?

Apart from Gulf countries, Giotrif® / Gilotrif® can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Giotrif® / Gilotrif® tablets in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Giotrif® / Gilotrif® Tablets online in India?

Yes, one can buy Giotrif® / Gilotrif® in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the supply of Giotrif® / Gilotrif® tablets through legal channels.

What are the storage conditions of Giotrif® / Gilotrif® Tablets?

Store Giotrif® / Gilotrif® 40 mg, 30 mg, and 20 mg at 20°C to 25°C (68°F to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). Dispense medicine in the original container to protect from exposure to high humidity and light.